1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

9 More Devices Get Class II Status From US FDA

 
• By Elizabeth Orr

The newly classified devices include innovative products from Medtronic, Canary Medical and AppliedVR, among others.

The US Food and Drug Administration has been on a classification binge lately, announcing the classification of nine new device types since the start of the year. All are former de novo products that will now be regulated as class II devices with special controls.

The most recent nine join six classification announcements made in late 2022, for a total of 15 classifications in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

EUDAMED Official Readiness Notice Due Any Day

The sector has been waiting long enough for one of the foundation stones of the implementation of the EU’s Medical Device and IVD Regulations. This month will see a landmark event.

EU Medtech Regulations: Key Updates Ahead of December Proposal

While anticipation grows around the European Commission’s forthcoming medtech proposal, due in mid-December, a series of EU documents have been published on topics including recertification, standards, changes to companion diagnostics and the latest notified body announcements.

What Do Money, Gender, And Politics Have To Do With Device Recalls? Quite A Lot

 
• By Brian Bossetta

During the MDIC Excellence in Quality Summit, an expert in product recalls offered several unconventional and somewhat controversial factors that impact how quickly device makers initiate a recall once they discover a problem.

Can Chatbots Treat Depression? FDA Advisers Urge Caution on Generative AI Tools

 
• By Elizabeth Orr

FDA advisers gave a cautious nod to the idea of using generative AI in mental healthcare during a Nov. 6 panel meeting, saying evidence-backed tools could help expand access – but warning that safety, oversight, and the irreplaceable human connection remain major unanswered questions.

More from Policy & Regulation

US FDA Appropriations Cut In Proposed Shutdown-Ending Agreement

 
• By Derrick Gingery

But the Senate’s reduction would not be as much as the House of Representatives and President Trump proposed earlier this year, which is likely a win for the agency.

Can Chatbots Treat Depression? FDA Advisers Urge Caution on Generative AI Tools

 
• By Elizabeth Orr

FDA advisers gave a cautious nod to the idea of using generative AI in mental healthcare during a Nov. 6 panel meeting, saying evidence-backed tools could help expand access – but warning that safety, oversight, and the irreplaceable human connection remain major unanswered questions.

Makary And Oz Tout Successes At Their Respective Agencies, Say They Are Breaking Down Walls

 
• By Brian Bossetta

Nearly one year into leading their agencies, US FDA Commission Marty Makary and CMS Administrator Mehmet Oz took to the stage together at the Milken Institute’s Future of Health Summit 2025 to highlight what they see as progress and lay out plans for the road ahead.